Form 4: Apellis VP Sells Shares for Tax Withholding

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 548 shares of common stock to cover tax withholding on Restricted Stock Units.

Summary

• James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
• The transaction involved the disposition of 548 shares of common stock on September 2, 2025.
• The shares were sold at a price of $28.077 per share.
• The purpose of the sale was to cover tax withholding obligations related to Restricted Stock Units (RSUs) that were released on August 29, 2025.
• Following this transaction, Mr. Chopas directly beneficially owns 53,657 shares of Apellis Pharmaceuticals common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to vested equity compensation, indicating a neutral impact on company sentiment.

Positives

• The underlying event, the release of Restricted Stock Units, represents vested compensation for the executive.
• The sale is an administrative action to fulfill tax obligations, indicating a routine compensation event rather than a discretionary divestment.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction, specifically a non-discretionary sale to cover tax obligations on vested equity compensation. Such transactions are common across all industries for executives receiving equity-based pay and do not typically reflect a change in the company's strategic direction or industry trends.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact on employees beyond the reporting executive's compensation.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of a relatively small number of shares by a corporate officer to cover tax withholding on vested Restricted Stock Units. This is a routine administrative event and does not provide new information that would alter the fundamental investment thesis for Apellis Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as this filing does not present a reason to change an existing investment position.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, James Chopas, Corporate Officer